当前位置:首页 - 行情中心 - 回盛生物(300871) - 财务分析 - 利润表

回盛生物

(300871)

  

流通市值:22.44亿  总市值:22.46亿
流通股本:1.66亿   总股本:1.66亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入691,386,248.86449,082,426.69230,412,076.041,022,900,792.34
营业收入691,386,248.86449,082,426.69230,412,076.041,022,900,792.34
二、营业总成本689,038,689.93441,156,049.35220,505,096.35963,090,087.96
营业成本544,725,663.44348,738,072.54174,701,792.35797,537,428.44
税金及附加6,546,315.164,225,093.911,872,147.468,842,751.6
销售费用40,862,437.8226,281,353.5813,059,442.4548,427,518.18
管理费用52,054,568.6733,609,313.7916,524,549.1154,045,250.45
研发费用31,206,491.1219,240,228.489,286,444.3240,138,389.37
财务费用13,643,213.729,061,987.055,060,720.6614,098,749.92
其中:利息费用16,618,173.0710,413,382.75,391,289.9618,375,863.81
其中:利息收入3,290,618.031,592,966.96677,042.974,757,845.13
加:公允价值变动收益4,270,265.743,858,963.411,732,296.071,461,361.06
加:投资收益6,094,052.683,189,297.171,133,671.515,548,630.18
资产处置收益---6,946.67
资产减值损失(新)-2,865,978.48-1,867,459.85-564,629.6-2,124,452.27
信用减值损失(新)518,366.311,866,982.49331,638.77-10,962,489.74
其他收益6,624,829.824,642,625.964,079,338.025,416,249.05
营业利润平衡项目0000
四、营业利润16,989,09519,616,786.5216,619,294.4659,156,949.33
加:营业外收入40,708.3940,561.8934,259.5294,751.22
减:营业外支出2,389,172.212,294,136.2822,086.52,542,200.15
利润总额平衡项目0000
五、利润总额14,640,631.1817,363,212.1316,631,467.4856,709,500.4
减:所得税费用-236,727.231,465,267.971,775,749.484,003,024.92
六、净利润14,877,358.4115,897,944.1614,855,71852,706,475.48
持续经营净利润14,877,358.4115,897,944.1614,855,71852,706,475.48
归属于母公司股东的净利润14,877,358.4115,897,944.1614,855,71852,706,475.48
(一)基本每股收益0.090.10.090.32
(二)稀释每股收益0.090.10.090.32
九、综合收益总额14,877,358.4115,897,944.1614,855,71852,706,475.48
归属于母公司股东的综合收益总额14,877,358.4115,897,944.1614,855,71852,706,475.48
公告日期2023-10-302023-08-292023-04-272023-04-27
审计意见(境内)标准无保留意见
TOP↑